1
|
Song Z, Zhang Y, Luo W, Sun C, Lv C, Wang S, He Q, Xu R, Bai Z, Chang X, Yang Y. HAND2-AS1 Promotes Ferroptosis to Reverse Lenvatinib Resistance in Hepatocellular Carcinoma by TLR4/NOX2/DUOX2 Axis. Curr Cancer Drug Targets 2024; 24:CCDT-EPUB-139022. [PMID: 38465433 DOI: 10.2174/0115680096279597240219055135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Revised: 01/11/2024] [Accepted: 01/23/2024] [Indexed: 03/12/2024]
Abstract
INTRODUCTION Lenvatinib resistance causes less than 40% of the objective response rate. Therefore, it is urgent to explore new therapeutic targets to reverse the lenvatinib resistance for HCC. HAND2-AS1 is a critical tumor suppressor gene in various cancers. METHODS Here, we investigated the role of HAND2-AS1 in the molecular mechanism of lenvatinib resistance in HCC. It was found that HAND2-AS1 was lowly expressed in the HepG2 lenvatinib resistance (HepG2-LR) cells and HCC tissues and associated with progression-free intervals via TCGA. Overexpression of HAND2-AS1 (OE-HAND2-AS1) decreased the IC50 of lenvatinib in HepG2-LR cells to reverse lenvatinib resistance. Moreover, OE-HAND2-AS1 induced intracellular concentrations of malondialdehyde (MDA) and lipid ROS and decreased the ratio of glutathione to glutathione disulfide (GSH/GSSG) to promote ferroptosis. RESULTS A xenograft model in which nude mice were injected with OE-HAND2-AS1 HepG2-LR cells confirmed that OE-HAND2-AS1 could reverse lenvatinib resistance and decrease tumor formation in vivo. HAND2-AS1 promoted the expression of ferroptosis-related genes (TLR4, NOX2, and DUOX2) and promoted ferroptosis to reverse lenvatinib resistance by increasing TLR4/ NOX2/DUOX2 via competing endogenous miR-219a-1-3p in HCC cells. Besides, patients with a low HAND2-AS1 level had early recurrence after resection. CONCLUSION These findings suggested that HAND2-AS1 may be a potential therapeutic target and an indicator of early recurrence for HCC.
Collapse
Affiliation(s)
- Zheng Song
- Peking University 302 Clinical Medical School, Beijing, China
- Department of Liver Disease of Chinese PLA General Hospital, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
| | - Yu Zhang
- Peking University 302 Clinical Medical School, Beijing, China
- Department of Liver Disease of Chinese PLA General Hospital, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
| | - Wei Luo
- Department of Liver Disease of Chinese PLA General Hospital, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
| | - Chao Sun
- Department of Liver Disease of Chinese PLA General Hospital, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
- Chinese People's Liberation Army (PLA) Medical School, Beijing, China
| | - Caihong Lv
- Peking University 302 Clinical Medical School, Beijing, China
- Department of Liver Disease of Chinese PLA General Hospital, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
| | - Sihao Wang
- Department of Liver Disease of Chinese PLA General Hospital, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
- Chinese People's Liberation Army (PLA) Medical School, Beijing, China
| | - Quanwei He
- Department of Liver Disease of Chinese PLA General Hospital, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
- Chinese People's Liberation Army (PLA) Medical School, Beijing, China
| | - Ran Xu
- Department of Liver Disease of Chinese PLA General Hospital, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
- Chinese People's Liberation Army (PLA) Medical School, Beijing, China
| | - Zhaofang Bai
- Department of Liver Disease of Chinese PLA General Hospital, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
| | - Xiujuan Chang
- Department of Liver Disease of Chinese PLA General Hospital, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
| | - Yongping Yang
- Peking University 302 Clinical Medical School, Beijing, China
- Department of Liver Disease of Chinese PLA General Hospital, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
| |
Collapse
|